- Details
- Description
Packaging Size:
21 capsules per bottle
Strength:
1.34 mg
Composition:
Tivozanib 1.34 mg per capsule, equivalent to 1.5 mg tivozanib hydrochloride.
Treatment:
Advanced renal cell carcinoma (RCC), particularly relapsed or refractory disease following prior systemic therapies.
Form:
Capsule
Brand:
Tivoxen
Quantity Unit:
1 capsule
Manufacturer:
Everest Pharmaceuticals Ltd.
Tivoxen 1.34 mg (Tivozanib) is a prescription targeted anticancer medicine used for the treatment of advanced renal cell carcinoma (RCC) in adults. Tivozanib is a selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor that blocks signals responsible for the growth of new blood vessels supplying tumors. By inhibiting these pathways, it helps slow tumor growth and disease progression. Treatment should be administered under the supervision of an oncology specialist, with regular monitoring for possible side effects.
